Skip to main content
Equibles

Affinity Asset Advisors, LLC

Position in CGEM — Cullinan Therapeutics, Inc.

CIK 1773195 NEW YORK, NY
Back to CGEM Full portfolio

Position in CGEM

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$15,947,589
+$4,845,885 QoQ
Shares Held
875,760
+12.1% QoQ
Ownership
1.36%
of shares outstanding
% of Portfolio
0.80%
of 13F equity value
Holder Rank
#17
of 183 holders
Holding Since
Jun 2021
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CGEM Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names. CGEM ranks #34 (0.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 3,750,000 $132,712,500
2 APGE
Apogee Therapeutics, Inc.
 987,000 $131,004,510
3 SYRE
Spyre Therapeutics, Inc.
 1,279,134 $113,561,516
4 XENE
Xenon Pharmaceuticals Inc.
 1,595,000 $96,274,200
5 ERAS
Erasca, Inc.
 5,250,000 $96,180,000
6 INSM
INSMED Inc
 650,000 $69,303,000
7 PRAX
Praxis Precision Medicines, Inc.
 185,000 $61,936,150
8 ORKA
Oruka Therapeutics, Inc.
 590,000 $56,150,300

All Filings in CGEM

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $15,947,589 875,760
2026-03-31 $11,101,704 781,260
2025-12-31 $19,997,297 1,932,106
2025-09-30 $1,564,434 263,817
2025-06-30 $1,986,542 263,817
2025-03-31 $1,997,094 263,817
2024-12-31 $3,213,291 263,817
2024-09-30 $4,416,296 263,817
2024-06-30 $4,600,968 263,817
2024-03-31 $4,406,339 258,588
2023-12-31 $3,057,000 300,000
2021-06-30 $1,158,750 45,000